Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The study has three parts. Part 1 is a dose escalation to investigate the safety and tolerability of ASP9521. Part 2 will evaluate the safety and tolerability and initial anti-tumor activity of ASP9521. Part 3 of the study will be a Food Effect study.
Full description
The purpose of the first study part is to investigate the safety and tolerability of ASP9521 in patients with Castrate Resistant Prostate Cancer. This will be done at different doses, starting at the lowest dose up to higher doses to find the maximum dose that is tolerated.
The second part will investigate the safety and tolerability and evaluate initial anti-tumor activity of ASP9521. This will be done at multiple doses which are identified in part 1 to potentially be effective. The number of patients in part 2 will be higher number compared to part I.
The third part of the study will investigate the effect of food on the drug in patients; this will be a crossover design fed to fasted and vice versa.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
Metastatic disease documented by 2 or more bone lesions on bone scan or by soft tissue disease observed by Computed tomography/Magnetic resonance imaging (CT/MRI)
Ongoing androgen deprivation with Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy or bilateral orchiectomy. For patients who have not had an orchiectomy, there must be a plan to maintain effective LHRH agonist/antagonist therapy for the duration of the study
Serum testosterone <1.7 nmol/L (50 ng/dL) at screening
Patients receiving bisphosphonates or other approved bone targeting therapy must have been on stable doses for at least 4 weeks prior to screening
Progressive disease at study entry defined as one or more of the following 3 criteria occurring in the setting of castrate levels of testosterone:
Life expectancy of >6 months according to the investigator's judgment
Chemotherapy-Naïve patients should be asymptomatic or controlled symptomatic patients with metastatic CRPC who have failed one or more lines of hormonal treatment/androgen deprivation therapy but have not received chemotherapy or have refused chemotherapy. Post chemotherapy patients should have received not more than two prior regimens of chemotherapy for prostate cancer, of which one is docetaxel-based
Exclusion criteria
Concomitant treatment with the following is prohibited:
Radiation therapy for treatment of the prostate within 3 months prior to screening
Radiation therapy for the treatment of metastases within 3 weeks (if single fraction of radiotherapy then within 2 weeks) and radionuclide therapy for the treatment of metastases within 4 weeks prior to screening
Major surgery within 2 months prior to screening
Known or suspected intracerebral disease or brain metastasis
Use of an investigational agent within 4 weeks prior to treatment allocation or a period required by local regulation, whichever is longer
Prior use, or participation in a clinical study, of an investigational agent that blocks androgen synthesis or targets the androgen receptor
Primary purpose
Allocation
Interventional model
Masking
13 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal